Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

S 301Sesión 222

Classifies 7 Hydroxymitragynine as Schedule I drug.

Statement

SENATE HEALTH, HUMAN SERVICES AND SENIOR CITIZENS COMMITTEE

STATEMENT TO

SENATE, No. 301

STATE OF NEW JERSEY

DATED:  MARCH 16, 2026

      The Senate Health, Human Services and Senior Citizens Committee reports favorably Senate Bill No. 301.

      This bill would classify 7 hydroxymitrgynine (7-OH) as a Schedule I controlled dangerous substance. 

      7-OH is one of the psychoactive alkaloids naturally found in the Mitragyna speciosa plant, commonly known as Kratom.  7-OH, in higher concentrations when metabolized by the body, can produce opioid-like effects and can have similarly addictive qualities.  Kratom, which contains 7-OH in lower concentrations in its natural form, is frequently marketed for its psychoactive and opioid-like analgesic effects and for use in the treatment of certain opioid addictions and withdrawal symptoms, a treatment which has not been conclusively proven.

      The federal Food and Drug Administration (FDA) has advised that 7-OH poses a threat to public health and has the potential for abuse because of its ability to blind opioid receptors in the brain.  The FDA has issued a number of warnings and conducted seizures of illegally sold, unapproved, or misbranded drug products containing potentially lethal doses of synthetic 7-OH, which contain higher concentrations of the psychoactive alkaloid.  Currently, Kratom and 7-OH have not been approved by the FDA for any medical use.  Further, on July 29, 2025, the FDA also recommended that 7-OH be scheduled under the federal “Controlled Substances Act,” 21 U.S.C.s.812.  Until the drug is scheduled under the federal act, 7-OH is not presently barred by federal law.  It is also not presently barred by New Jersey law.

      Under this bill, 7-OH would be classified as a Schedule I drug in this State.  7-OH would be placed on the Schedule I list of the “New Jersey Controlled Dangerous Substances Act,” P.L.1970, c.226 (C.24:21-1 et seq.), which would define the drug as a substance that: (1) has high potential for abuse; and (2) has no accepted medical use in treatment in the United States; or lacks accepted safety for use in treatment under medical supervision.

      By classifying 7-OH as a Schedule I drug, under the “Comprehensive Drug Reform Act of 1987,” N.J.S.2C:35-1 et seq., the drug would be considered illegal controlled dangerous substances for which manufacturing, distribution, or possession with intent to manufacture or distribute would be punishable as either: a crime of the second degree, if the act involved a quantity of one ounce or more; or a crime of the third degree, if the act involved less than one ounce. 

      This bill was prefiled for introduction in the 2026-2027 session pending technical review.  As reported, the bill includes the changes required by technical review, which has been performed.

Texto oficial de la Legislatura de New Jersey. El formato se adaptó para leerlo en Ratifi.